Search

everythinglearnresearchcommunity

for

Search:↓

The conversation is about a hair loss treatment regimen that does not include finasteride. Specific treatments used are not mentioned.

Pyrilutamide is discussed as a potential hair loss treatment, acting as an androgen receptor antagonist. The conversation questions if it can maintain hair long-term without using finasteride.

RU58841 is preferred over finasteride for blocking DHT on the scalp, especially for those with aggressive MPB. Creatine is associated with increased hair shedding, even when using RU58841.

A user discussed a significant hair recovery using alfatradiol and fluridil but was considered untrustworthy and the post was deleted. They are seeking the original poster's username.

A user experienced increased hair fall after switching from a minoxidil, tretinoin, and azelaic acid combo to minoxidil only. They are concerned if the shedding is normal or due to stopping tretinoin and azelaic acid.

DHT is essential for androgenetic alopecia, not testosterone. Treatments like finasteride and dutasteride reduce DHT, halting hair loss.

Alfatradiol is used as a mild treatment to slow or stabilize hair loss, often alongside finasteride and pumpkin seed oil. Users report reduced shedding and minimal side effects, but minoxidil is noted as more effective for regrowth.

Veradermics has a market cap over a billion dollars, comparable to Cosmo pharmaceutical. Users discuss using Kintor's Pirylutamide for hair loss.

Despite using dutasteride, RU58841, minoxidil, and ketoconazole for years, the user continues to experience severe hair loss and thinning. They seek advice after multiple dermatologists confirmed androgenetic alopecia (AGA) but offered no effective solutions.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

The user experienced excessive scalp oiliness and high testosterone levels after switching from finasteride to dutasteride. They plan to manage their condition with finasteride and are considering spironolactone to reduce testosterone and restore dry skin.

A compound called MTP3 from the Monoterpene family was found to be safe and highly effective at treating hair loss by inhibiting the FGF5 gene, but its identity is undisclosed for commercial reasons. No specific treatments like Minoxidil, finasteride, or RU58841 were discussed.

Finasteride can cause oily skin and acne due to increased testosterone or sensitivity of androgen receptors. Some users find dutasteride results in less oily skin compared to finasteride.

A new product, a retinoic acid solution (0.3%), is available to enhance minoxidil products like Rogaine and Kirkland by converting them into a tretinoin-containing solution for improved hair loss treatment. One unit of the product is enough for a year's supply.

ET-02 is seen as promising for addressing hair loss and graying, but PP405 is more advanced in development and has better publicity. Some users plan to use both treatments alongside minoxidil and dutasteride.

1% finasteride is considered too high, with most people using 0.1% or 0.3% topically. Combining it with 0.1% tretinoin is aggressive and may cause skin irritation.

PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.

The user has been using 0.5mg daily dutasteride for a year without seeing progress and previously used oral finasteride and topical minoxidil. They are considering a hair transplant and discussing various treatments like scalp massages, derma rolling, and different medication dosages.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

The user is asking about the effectiveness of tretinoin 0.025% for hair loss, noting significant beard growth since using it for acne. They are considering adding it to their hair loss treatment regimen.

Creatine might increase hair loss due to increased DHT sensitivity, but evidence is mostly anecdotal. The user is using oral minoxidil for hair loss and is cautious about starting creatine.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

A 16-year-old experiencing hair thinning noticed a shift from shedding long hairs to shorter hairs, while using Vitamin D, biotin supplements, ketoconazole shampoo, and improving diet. They are questioning if the short hairs indicate regrowth or androgenetic alopecia (AGA).

A topical serum made from monounsaturated fatty acids showed rapid hair growth in mice within 20 days, but it remains experimental for humans. Users humorously discussed the frequent success of hair growth treatments in mice and expressed skepticism about translating these results to humans.

A user's results after using finasteride (1.25mg/day) for one year, which included improvements to their hair and skin as well as some side effects such as decreased libido and watery semen. They also mentioned they stopped taking creatine around the same time.

Topical melatonin may help reduce hair loss and increase hair thickness in people with androgenetic alopecia (AGA), with some studies showing positive results. It can be mixed with minoxidil for application, and its effectiveness might be enhanced when used with micro-needling, but results may vary among individuals.

The user is considering mixing 15mg of dutasteride with 60ml of castor oil for mesotherapy (micro-needling) to treat hair loss. They are asking if this method is viable.

PP405 is a potential hair loss treatment, but its safety and effectiveness are uncertain. Users advise caution and suggest waiting for more data before purchasing unverified versions.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

Concerns about the long-term safety of VDPHL01, an extended-release minoxidil, due to potential risks similar to Cantu syndrome, were raised, highlighting the lack of monitoring for chronic connective tissue changes. The conversation suggests that while the treatment may improve hair growth, it could lead to issues not detected in short-term trials.